Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

RGNX vs ZVRA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ZVRA Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 8–2 Matrix Metrics)

ZVRA Overall Winner 6-Pillar Tally: RGNX 1 – 5 ZVRA Matrix Metrics: RGNX 2 – 8 ZVRA

As of Nov 16, 2026, Zevra Therapeutics, Inc. (ZVRA) is the stronger overall head-to-head candidate over REGENXBIO Inc. (RGNX) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). RGNX carries a Unified Composite Score of 45.3/100 (HOLD) at $7.45 (N/M Forward P/E, -120.4% operating margin), whereas ZVRA carries 49.4/100 (HOLD) at $9.21 (9.3x Forward P/E, 31.5% operating margin).

  • Technical & Structure Timing Caution: RGNX is currently in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 48.3); meanwhile ZVRA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 38.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About RGNX vs ZVRA
RGNX NASDAQ
REGENXBIO Inc.
Biological Products, (No Disgnostic Substances)
$7.45
-2.49% 1D
Market Cap $500.9M
TTM Revenue $154M
Forward P/E N/M
Beta / 30D Vol 1.82β · 76% Vol
Unified Composite Score
45.3 / 100 HOLD
Tech 36.0 Fund 44.0 Flow 69.0 Mom 50.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -12.2%) with fading momentum, RSI 48
RSI-14: 48.3 · SMA20: $7.42 · SMA50: $7.63
ZVRA NASDAQ Head-to-Head Winner
Zevra Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$9.21
+1.49% 1D
Market Cap $664.1M
TTM Revenue $148M
Forward P/E 9.3x
Beta / 30D Vol 1.18β · 95% Vol
Unified Composite Score
49.4 / 100 HOLD
Tech 37.0 Fund 53.0 Flow 67.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -4.4%), weak momentum, RSI 39
RSI-14: 38.9 · SMA20: $10.53 · SMA50: $10.92

6-Pillar Scorecard Institutional Category Breakdown (RGNX 1 – 5 ZVRA)

Columns: Metric · RGNX · ZVRA
1. Valuation Multiples ZVRA
Forward P/E N/M 9.3x
Trailing P/E N/M 9.7x
PEG Ratio 0.26x 10.67x
EV / Revenue 3.1x 3.7x
2. Growth & Scale ZVRA
Revenue Growth (YoY) -69.2% +44.9%
Earnings Growth (YoY) +0.0% -88.4%
TTM Revenue (USD) $154M $148M
Market Cap $500.9M $664.1M
3. Profitability & Quality ZVRA
Gross Margin -64.5% 95.4%
Operating Margin -120.4% 31.5%
Net Profit Margin -113.9% 52.8%
Return on Equity (ROE) -113.2% 41.9%
4. Balance Sheet & Cash Flow ZVRA
Cash Generation (TTM) -$155M $38M
Cash Flow Margin -100.6% 25.9%
Net Cash / Leverage $29M Net Cash $121M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning RGNX
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 349.6% (52nd %ile) 71.7% (14th %ile)
Put/Call OI Skew N/A 1.62x (Put-Skewed)
OBV Trend / Tech Phase ACCUMULATION · Distribution DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat ZVRA
OpEx & R&D Intensity 55.9% of Rev ($86M) 63.9% of Rev ($94M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: RGNX (2) vs ZVRA (8)
Institutional Metric RGNX ZVRA Criterion Row Edge
Market Capitalization
Scale
$500.9M $664.1M Larger Scale ZVRA
Trailing P/E Ratio
Valuation
N/M 9.7x Lower Multiple ZVRA
Forward P/E Ratio
Valuation
N/M 9.3x Lower Multiple ZVRA
Revenue Growth (YoY)
Growth
-69.2% +44.9% Higher Growth ZVRA
Operating Margin (TTM)
Profitability
-120.4% 31.5% Higher Margin ZVRA
Net Profit Margin
Profitability
-113.9% 52.8% Higher Margin ZVRA
Return on Equity (ROE)
Capital Efficiency
-113.2% 41.9% Higher ROE ZVRA
52-Week Range Position
Momentum
19% ($5–$16) 17% ($8–$15) Stronger Trend RGNX
Beta / 30D Volatility
Risk Regime
1.82β · 76% Vol 1.18β · 95% Vol Lower Realized Risk RGNX
Unified Institutional Score
Composite Signal
45.3 / 100 (HOLD) 49.4 / 100 (HOLD) Higher Composite ZVRA
Trailing 12M Revenue (USD)
Operating Scale
$154M $148M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
-64.5% 95.4% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.26x PEG · 3.1x EV/Rev 10.67x PEG · 3.7x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$155M ($29M Net Cash) $38M ($121M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon RGNX +14.87 pp
RGNX: +7.58% · ZVRA: -7.29%
3M Horizon ZVRA +12.35 pp
RGNX: -32.7% · ZVRA: -20.35%
6M Horizon RGNX +43.51 pp
RGNX: +31.86% · ZVRA: -11.65%
1Y Horizon ZVRA +35.84 pp
RGNX: -36.0% · ZVRA: -0.16%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period RGNX Revenue ZVRA Revenue RGNX Op. Margin ZVRA Op. Margin Margin Leader
FY2018 $220M N/A 40.3% N/A RGNX
FY2019 $40M $10M -422.9% -158.4% ZVRA
FY2020 $150M $10M -77.1% -42.2% ZVRA
FY2021 $470M $30M 34.0% 27.0% RGNX
FY2022 $110M $10M -233.2% -418.9% RGNX
FY2023 $90M $30M -297.1% -180.6% ZVRA
FY2024 $80M $20M -280.0% -368.5% RGNX
FY2025 $170M $110M -94.6% -59.1% ZVRA

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
RGNX BREAKDOWN
91d in phase · OBV ACCUMULATION
Current IV 349.6%
IV Percentile 52nd %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact RGNX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ZVRA BREAKDOWN
111d in phase · OBV DISTRIBUTION
Current IV 71.7%
IV Percentile 14th %ile
Put/Call OI Skew 1.62x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact ZVRA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
RGNX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $500.9M market capitalization and -120.4% operating margin.
OpEx & R&D Reinvestment 55.9% of Rev ($86M)
90D Engineering Disclosures 0 Published
ZVRA Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $664.1M market capitalization and 31.5% operating margin.
OpEx & R&D Reinvestment 63.9% of Rev ($94M)
90D Engineering Disclosures 0 Published

Investor FAQ RGNX vs ZVRA Key Questions & Quantitative Answers

As of Nov 16, 2026, Zevra Therapeutics, Inc. (ZVRA) is the stronger overall head-to-head candidate over REGENXBIO Inc. (RGNX) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). RGNX carries a Unified Composite Score of 45.3/100 (HOLD) at $7.45 (N/M Forward P/E, -120.4% operating margin), whereas ZVRA carries 49.4/100 (HOLD) at $9.21 (9.3x Forward P/E, 31.5% operating margin). Technical & Structure Timing Caution: RGNX is currently in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 48.3); meanwhile ZVRA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 38.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ZVRA leads the Growth & Scale pillar: RGNX posts -69.2% YoY revenue growth and +0.0% YoY earnings growth on $154M TTM revenue (-64.5% gross margin, -120.4% operating margin), compared with ZVRA at +44.9% YoY revenue growth and -88.4% YoY earnings growth on $148M TTM revenue (95.4% gross margin, 31.5% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), RGNX cumulative revenue shifted -22.7% while ZVRA shifted +1000.0%. In operating R&D and SG&A reinvestment, RGNX deploys 55.9% of Rev ($86M) (0 90-day corporate R&D disclosures) versus 63.9% of Rev ($94M) (0 disclosures) for ZVRA.

ZVRA screens cheaper on headline valuation multiples. RGNX trades at N/M Forward P/E, N/M Trailing P/E, 0.26x PEG, and 3.1x EV/Revenue (-100.6% FCF margin), whereas ZVRA trades at 9.3x Forward P/E, 9.7x Trailing P/E, 10.67x PEG, and 3.7x EV/Revenue (25.9% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against RGNX (-113.2% ROE) versus ZVRA (41.9% ROE) capital efficiency.

In options market volatility and institutional positioning, RGNX carries 349.6% implied volatility (52nd %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.82β · 76% Vol realized risk). By comparison, ZVRA carries 71.7% implied volatility (14th %ile, Compressed (<25th %ile)), a 1.62x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.18β · 95% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.